More than half of chronic rhinosinusitis with nasal polyps (CRSwNP) patients treated with dupilumab experience early and fast olfactory improvement within 28 days

Documenti analoghi

• Almost Half of the Dupilumab‐Treated Patients With Severe Chronic Rhinosinusitis With Nasal Polyps Achieve Remission in One Year
  di: Josje J. Otten, et al.
  Pubblicazione: (2025)
• Real‐world data show sustained therapeutic effects of dupilumab in chronic rhinosinusitis with nasal polyps (CRSwNP) over 3 years
  di: Patrick Huber, et al.
  Pubblicazione: (2024)
• “Super‐Responders” to Dupilumab Treatment in Patients With Primary Diffuse Chronic Rhinosinusitis With Nasal Polyps
  di: P. E. Vonk, et al.
  Pubblicazione: (2025)
• Perioperative adjuvant therapy with short course of dupilumab with ESS for recurrent CRSwNP
  di: Audrey Pelletier, et al.
  Pubblicazione: (2024)
• Two‐Year Data of Tapered Dupilumab Shows High Effectiveness in Chronic Rhinosinusitis with Nasal Polyps With Nonsteroidal Anti‐inflammatory Drug‐Exacerbated Respiratory Disease
  di: H. B. E. Elzinga, et al.
  Pubblicazione: (2025)